The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid Arthritis
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
Rheumatoid arthritis (RA) is a systemic chronic arthritis characterized by systemic
inflammation, persistent synovitis and final joint destruction Inflammatory diseases can lead
to decreased productivity and impaired health-related quality of life. As a chronic disease,
rheumatoid Chronic arthritis needs long-term treatment. At the same time, RA can cause skin,
eye, lung, liver, kidney, blood and cardiovascular diseases All of them were extraarticular
lesions. It causes a heavy burden to the patients themselves, their families and the society.
The main clinical manifestations of RA were morning stiffness Joint swelling and pain,
cartilage destruction and joint space narrowing, if not treated, will lead to joint
destruction, deformity and dysfunction The rate of disability is high. As a new drug in the
treatment of RA, tofacitinib can relieve RA symptoms and promote joint healing It can recover
the injury and correct the abnormal immune function. At present, studies have proved that the
traditional anti rheumatic drugs are ineffective in the treatment of RA. The addition of
tofacitinib to patients may be beneficial to the treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University